Aclarion Hits Another Key Milestone by Adding Vitality - Third Major Payer to Cover Nociscan in Greater UK
Aclarion (NASDAQ: ACON) has achieved a significant milestone by securing coverage for its Nociscan technology from Vitality, the third major private health insurer in the UK. This addition means Aclarion now has coverage from 3 of the 4 largest private health insurers in the UK, providing access to nearly 60% of patients with private health insurance in the Greater London market.
Nociscan, a SaaS platform that helps physicians identify the location of chronic low back pain, is gaining traction in the UK healthcare market. The London Clinic, a renowned independent hospital, has played a important role in demonstrating Nociscan's value and securing payer coverage. Aclarion's CEO, Brent Ness, expects this success to be replicated across their 10 KOL sites globally.
With private medical insurance becoming increasingly popular in the UK, these coverage decisions represent a significant shift in Aclarion's business model, providing a clear path to commercialization in the UK market.
Aclarion (NASDAQ: ACON) ha raggiunto un traguardo significativo ottenendo la copertura per la sua tecnologia Nociscan da parte di Vitality, il terzo maggiore assicuratore sanitario privato nel Regno Unito. Questa aggiunta significa che Aclarion ora ha copertura da 3 dei 4 maggiori assicuratori sanitari privati nel Regno Unito, garantendo l'accesso a quasi il 60% dei pazienti con assicurazione sanitaria privata nel mercato della Grande Londra.
Nociscan, una piattaforma SaaS che aiuta i medici a identificare la posizione del dolore cronico alla schiena, sta guadagnando terreno nel mercato sanitario del Regno Unito. La London Clinic, un rinomato ospedale indipendente, ha svolto un ruolo importante nel dimostrare il valore di Nociscan e nell'assicurare la copertura dai pagatori. Il CEO di Aclarion, Brent Ness, prevede che questo successo venga replicato nei loro 10 siti KOL a livello globale.
Con l'assicurazione medica privata che diventa sempre più popolare nel Regno Unito, queste decisioni di copertura rappresentano un cambiamento significativo nel modello di business di Aclarion, offrendo un chiaro percorso verso la commercializzazione nel mercato britannico.
Aclarion (NASDAQ: ACON) ha alcanzado un hito significativo al obtener la cobertura para su tecnología Nociscan de Vitality, el tercer mayor asegurador de salud privado en el Reino Unido. Esta adición significa que Aclarion ahora tiene cobertura de 3 de los 4 mayores aseguradores de salud privados en el Reino Unido, lo que proporciona acceso a casi el 60% de los pacientes con seguro de salud privado en el mercado de Gran Londres.
Nociscan, una plataforma SaaS que ayuda a los médicos a identificar la ubicación del dolor crónico lumbar, está ganando terreno en el mercado de la salud del Reino Unido. La London Clinic, un famoso hospital independiente, ha desempeñado un papel importante en la demostración del valor de Nociscan y en asegurar la cobertura de los aseguradores. El CEO de Aclarion, Brent Ness, espera que este éxito se replique en sus 10 sitios KOL a nivel mundial.
Con el seguro médico privado volviéndose cada vez más popular en el Reino Unido, estas decisiones de cobertura representan un cambio significativo en el modelo de negocio de Aclarion, proporcionando un camino claro hacia la comercialización en el mercado británico.
Aclarion (NASDAQ: ACON)은 Vitality로부터 Nociscan 기술에 대한 보장을 확보하여 중요한 이정표를 달성했습니다. 이는 Aclarion이 이제 영국의 4대 주요 민간 건강 보험사 중 3곳으로부터 보장을 확보했음을 의미하며, 그로 인해 그레이터 런던 시장에서 민간 건강 보험을 보유한 환자의 거의 60%에 접근할 수 있게 되었습니다.
Nociscan은 만성 요통의 위치를 식별하는 데 도움을 주는 SaaS 플랫폼으로, 영국 의료 시장에서 주목받고 있습니다. 유명한 독립 병원인 런던 클리닉은 Nociscan의 가치를 입증하고 보험사 보장을 확보하는 데 중요한 역할을 했습니다. Aclarion의 CEO인 Brent Ness는 이 성공이 전 세계 10개의 KOL 사이트에서 재현되기를 기대하고 있습니다.
영국에서 민간 의료보험이 점점 더 인기를 끌고 있는 가운데, 이러한 보장 결정은 Aclarion의 비즈니스 모델에 중대한 변화를 나타내며, 영국 시장에서 상업화로 가는 명확한 경로를 제공합니다.
Aclarion (NASDAQ: ACON) a atteint un jalon important en obtenant la couverture de sa technologie Nociscan de la part de Vitality, le troisième plus grand assureur santé privé au Royaume-Uni. Cet ajout signifie qu'Aclarion possède désormais une couverture de 3 des 4 plus grands assureurs santé privés au Royaume-Uni, offrant un accès à près de 60% des patients ayant une assurance santé privée sur le marché de la Grande Londres.
Nociscan, une plateforme SaaS qui aide les médecins à identifier la localisation des douleurs lombaires chroniques, est en train de gagner du terrain sur le marché de la santé britannique. La London Clinic, un hôpital indépendant de renom, a joué un rôle important dans la démonstration de la valeur de Nociscan et dans l'obtention de la couverture des payeurs. Le PDG d'Aclarion, Brent Ness, s'attend à ce que ce succès se reproduise dans leurs 10 sites KOL à l'international.
Avec l'assurance médicale privée devenant de plus en plus populaire au Royaume-Uni, ces décisions de couverture représentent un changement significatif dans le modèle commercial d'Aclarion, offrant un chemin clair vers la commercialisation sur le marché britannique.
Aclarion (NASDAQ: ACON) hat einen bedeutenden Meilenstein erreicht, indem es die Abdeckung seiner Nociscan-Technologie von Vitality, dem drittgrößten privaten Krankenversicherer im Vereinigten Königreich, gesichert hat. Diese Ergänzung bedeutet, dass Aclarion jetzt von 3 der 4 größten privaten Krankenversicherer im Vereinigten Königreich abgedeckt wird, was den Zugang zu fast 60% der Patienten mit privater Krankenversicherung im Großraum London ermöglicht.
Nociscan, eine SaaS-Plattform, die Ärzten hilft, den Standort von chronischen Rückenschmerzen zu identifizieren, gewinnt im britischen Gesundheitsmarkt an Bedeutung. Die London Clinic, ein renommiertes unabhängiges Krankenhaus, hat eine wichtige Rolle bei der Demonstration des Wertes von Nociscan und der Sicherstellung der Zahlen übernommen. Aclarions CEO Brent Ness erwartet, dass dieser Erfolg an ihren 10 KOL-Stätten weltweit wiederholt wird.
Da private Krankenversicherungen im Vereinigten Königreich zunehmend beliebter werden, stellen diese Abdeckungsentscheidungen einen signifikanten Wandel im Geschäftsmodell von Aclarion dar und bieten einen klaren Weg zur Kommerzialisierung im britischen Markt.
- Secured coverage from 3 of the 4 largest private health insurers in the UK
- Nearly 60% of patients with private health insurance in Greater London now have access to Nociscan
- Clear path to commercialization in the UK market established
- Adoption by The London Clinic, a renowned independent hospital, after only 20 patients
- Potential for replication of success across 10 KOL sites globally
- None.
Insights
The addition of Vitality as the third major payer to cover Nociscan in the UK marks a significant milestone for Aclarion. With nearly
This coverage decision could accelerate Aclarion's revenue growth and market penetration in the UK. The company's strategy of partnering with clinical leaders to demonstrate value before seeking payer coverage appears effective and could be replicated in other markets, potentially leading to faster global expansion. However, investors should monitor the pace of adoption among physicians and patients, as well as any potential competitors entering this space.
This news represents a pivotal moment for Aclarion's commercialization efforts. Securing coverage from three major private insurers in the UK significantly improves the company's revenue potential. With an estimated
Investors should note that this development could lead to a faster path to profitability for Aclarion. The company's SaaS model, combined with broader insurance coverage, could result in recurring revenue streams and improved financial stability. However, it's important to monitor the company's ability to scale operations and manage costs as demand potentially increases. Future financial reports should be closely watched for evidence of revenue growth and margin improvements resulting from these coverage decisions.
Aclarion's success in securing coverage from three major UK insurers demonstrates strong market acceptance of Nociscan. This rapid adoption in the UK market could serve as a blueprint for expansion into other regions, potentially accelerating global market penetration. The company's strategy of leveraging key opinion leaders (KOLs) to drive payer coverage appears effective and scalable.
With low back pain affecting up to one-third of UK adults annually, the addressable market is substantial. However, investors should consider potential challenges such as competition from alternative diagnostic methods and the need for continued clinical validation. The company's ability to replicate this success in the U.S. and other markets will be important for long-term growth. Monitoring adoption rates among physicians and patient satisfaction will be key indicators of Nociscan's potential to become a global standard in chronic low back pain diagnosis.
- Vitality is a top 4 Provider of Private Medical Insurance in the UK.
- Aclarion now has Payer Coverage From 3 of the 4 Largest Private Health Insurers in the UK.
- Nearly
60% of all Patients With Private Health Insurance in the Greater London Market now Have Access to Aclarion’s Nociscan.
BROOMFIELD, CO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today their third payer coverage of Nociscan by Vitality in London, UK in conjunction with The London Clinic, one of the UK’s largest and most renowned independent hospitals. With the addition of coverage by Vitality, payer coverage for Nociscan is now available from three major private medical insurance groups in the UK, a global healthcare market with more than nine million residents.
“With three of the top four private payer systems in greater London covering Nociscan, we expect to see further coverage and strong product adoption in the UK market,” said Brent Ness, CEO of Aclarion. “These coverage decisions support the movement of Nociscan into the standard of care and further validate our strategy of partnering with strong clinical leaders in each market to let them see the value of our technology for improving surgical decisioning and then supporting these clinical leaders as they take Nociscan to the payers for coverage. The London Clinic team saw the value in Nociscan after only 20 patients and have thus far delivered payer coverage from 3 of the top 4 private health insurance payers in the market. We expect to replicate The London Clinic success in driving payer coverage at each of our 10 KOL sites in the U.S. and elsewhere around the world.”
In the UK, self-pay and private medical insurance are estimated to represent nearly
John Lorbiecki, Aclarion CFO, added, “These significant payer coverage decisions represent a sea change in our business. Every medical technology or services company faces the same dilemma of bringing new products to market. Without insurance companies paying for a technology or service, the revenue challenge is obvious. As soon as insurance companies recognize new innovations with an assigned payment, the economics change considerably. We now have a clear path to commercialization in the UK and will be allocating resources accordingly.”
Low back pain is estimated to affect up to one third of the UK adult population each year. The London Spine Clinic is the first private specialist spinal unit in England and their expert spine physicians have adopted Nociscan as an important decision support tool to be used when diagnosing and treating chronic low back pain. Nociscan is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine by quantifying chemical biomarkers demonstrated to be associated with disc pain. This biomarker data is entered into proprietary algorithms to highlight if a disc may be a source of pain, and when used with other diagnostic tools, provides critical insights into the location of a patient’s low back pain.
For more information about The London Clinic, please visit: www.thelondonclinic.co.uk
For more information about the London Spine Clinic, please visit: www.londonspineclinic.com
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company's current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes" and "expects" or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company's current plans and expectations, as well as future results of operations and financial condition. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Disclosure
The information stated above was prepared by Aclarion and reflects solely the opinion of Aclarion. Nothing in this statement shall be construed to imply any support or endorsement of Aclarion or any of its products by The London Clinic.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
646.823.8656
ksmith@pcgadvisory.com
Media Contacts:
Jodi Lamberti
SPRIG Consulting
612.812.7477
jodi@sprigconsulting.com
FAQ
What is the significance of Vitality covering Aclarion's Nociscan technology?
How does Nociscan help in diagnosing chronic low back pain?
What impact does this coverage have on Aclarion's (ACON) business model?
How prevalent is low back pain in the UK population?
